Investment
Features
FeesSafety
Academy
More
Pluang+

Flex to present at Goldman Sachs Communacopia + Technology Conference on Sept 9, 2026.

Market News
03 Sep 2026
PRNewsWire
View Source
Neutral
pluang ai news

Flex announced its leadership team will present at the Goldman Sachs Communacopia + Technology Conference on September 9, 2026. The presentation will be webcast live and available for replay on Flex's investor relations website. This event highlights Flex's role in advanced manufacturing and technology solutions, especially in AI-driven data center infrastructure. Investors can gain insights into Flex's strategies and innovations during the conference.

More News

Teladoc Health cuts 2026 revenue forecast amid insider stock sale and BetterHelp struggles

Teladoc Health cuts 2026 revenue forecast amid insider stock sale and BetterHelp struggles

Teladoc Health's BetterHelp segment saw an 11.6% revenue drop and a near-zero profit margin in Q2 2026, partly due to a shift from cash to insurance payments. The company lowered its full-year 2026 revenue guidance to $2.36-$2.45 billion from $2.48-$...

Market News
Bearish
17 minutes ago
Zscaler shares jump after beating Q4 earnings and revenue estimates, driven by AI focus.

Zscaler shares jump after beating Q4 earnings and revenue estimates, driven by AI focus.

Zscaler reported strong fiscal Q4 results, surpassing analyst expectations with an EPS of $1.19 and revenue of $898.19 million, a 25% year-over-year growth. The company credits its robust performance to strategic investments in artificial intelligenc...

Company Fundamentals
Bullish
21 minutes ago
Ciena shares drop 11% despite strong Q3 earnings and AI-driven demand growth.

Ciena shares drop 11% despite strong Q3 earnings and AI-driven demand growth.

Ciena reported a strong Q3 2026 with adjusted EPS of $2.11, a 215% increase year-over-year, and revenue up 37% to $1.67 billion, driven by high demand from cloud and AI data centers. The company’s backlog rose to $8.5 billion, signaling strong future...

Company Fundamentals
Neutral
1 hour ago
Kazia Therapeutics advances cancer drug trials with strong financial backing and upcoming earnings report.

Kazia Therapeutics advances cancer drug trials with strong financial backing and upcoming earnings report.

Kazia Therapeutics is progressing its main cancer drug candidate, paxalisib, into Phase 2 trials for colorectal cancer and planning a new breast cancer study. The company recently raised $40 million to support these developments and maintains a stron...

Company Fundamentals
Bullish
1 hour ago
Hutchison China MediTech upgraded to Buy after $1.3B GSK licensing deal for cancer drug.

Hutchison China MediTech upgraded to Buy after $1.3B GSK licensing deal for cancer drug.

Hutchison China MediTech Limited (HCM) received a Buy rating upgrade from Daiwa with a new price target of $18.50 following a major licensing deal with GSK. The agreement grants GSK exclusive rights to commercialize HCM's experimental cancer therapy ...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App